|
See related Gardasil vaccine information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine |
|
Indications |
Prevention of cervical, vulvar & vag cancer, genital warts & precancerous or dysplastic lesions eg cervical adenocarcinoma in situ (AIS), cervical intraepithelial neoplasia (CIN) grades 2 or 3, vulvar intraepithelial neoplasia (VIN) grades 2 & 3, vag intraepithelial neoplasia (VaIN) grades 2 & 3, CIN grade 1 in girls & women 9-45 yr. Prevention of genital warts caused by HPV types 6 & 11 in males 9-26 yr.
Click to view Gardasil detailed prescribing infomation |
|
Dosage |
0.5 mL IM in the deltoid region of the upper arm or in the higher anterolateral area of the thigh, according to the following schedule: 1st dose: At elected date; 2nd dose: 2 mth after the 1st dose; 3rd dose: 6 mth after the 1st dose.
Click to view Gardasil detailed prescribing infomation |
|
Overdosage |
View Gardasil overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity.
Click to view Gardasil detailed prescribing infomation |
|
Special Precautions |
Not for treatment of active external genital lesions; cervical, vulvar, vag or anal cancers; CIN, VIN or VaIN or AIN. Impaired immune response, thrombocytopenia or any coagulation disorder. Do not inject intravascularly, SC or intradermal. Pregnancy. Adult >45 yr. Childn <9 yr.
Click to view Gardasil detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, pyrexia; erythema, pain & swelling.
View ADR Monitoring Form |
|
Side Effects |
View Gardasil side effects |
|
Drug Interactions |
Immunosuppressants.
View more drug interactions with Gardasil |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Gardasil storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Gardasil description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Gardasil mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
